XNAS
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | Q1 2026 | -0.10 | -0.11 | -10.00% | $14,950 | ❌ Miss | -3.49% | -2.81% | — |
| 2026-03-25 | Q4 2025 | -0.12 | -0.13 | -8.33% | $171,895 | ❌ Miss | -5.10% | -10.53% | +7.50% |
| 2025-11-14 |
| Q3 2025 |
| -0.12 |
| -0.13 |
| -8.33% |
| $18,149 |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-06 | Q2 2025 | -0.14 | -0.10 | +28.57% | $70,588 | ✅ Beat | -5.85% | -15.35% | -15.55% |
| 2025-03-14 | Q4 2024 | -0.12 | -0.28 | -133.33% | $27,179 | ❌ Miss | +10.23% | +10.70% | -17.21% |
| 2024-11-08 | Q3 2024 | — | -0.23 | — | $36,031 | — | -12.11% | +11.05% | +14.47% |
| 2024-05-10 | Q1 2024 | — | -0.14 | — | $78,671 | — | -3.28% | +2.34% | -48.44% |
| 2024-03-27 | Q4 2023 | — | -0.10 | — | $20,536 | — | — | — | — |
Showing last 8 quarters.